Методика жидкостной биопсии в диагностике опухолей центральной нервной системы

Закрыть метаданные

Рекомендуем статьи по данной теме:

Экзосомальные некодирующие рнк как потенциальные биомаркеры в диагностике и прогнозировании рака легкого. Обзор литературы. Лабораторная служба. 2024;(3):42-49

Для постановки гистологического диагноза необходим образец опухолевой ткани, полученный путем биопсии. Этот метод сопряжен с рядом трудностей, особенно в нейроонкологии. В настоящее время разрабатывается альтернативный подход, известный как жидкостная биопсия (ЖБ). Он основан на анализе биологических сред организма на предмет наличия опухолевой ДНК и других биомаркеров. Это менее инвазивный метод диагностики, который может помочь преодолеть «недостатки» традиционной тканевой биопсии.

ЦЕЛЬ ИССЛЕДОВАНИЯ

Анализ литературы для оценки возможностей клинического применения данного метода и описания текущих проблем, связанных с его использованием.

МАТЕРИАЛ И МЕТОДЫ

В работе был проведен анализ литературы с применением поисковой системы PubMed на глубину поиска до 18 лет.

РЕЗУЛЬТАТЫ

Основными мишенями, используемыми в ЖБ, являются циркулирующие опухолевые клетки, внеклеточные везикулы, свободная циркулирующая ДНК и микро-РНК опухоли. Анализ данных биомаркеров является перспективным методом в диагностике и оценке динамики течения заболевания в нейроонкологии. Однако эта техника еще малоизучена и имеет ограничения, поэтому требуются дальнейшие исследования ее возможностей для более широкого применения в клинической практике.

ЗАКЛЮЧЕНИЕ

Сегодня совместное использование тканевой и ЖБ может улучшить точность диагностики, оценку прогноза и определение эффективности лечения при опухолях центральной нервной системы.

Ключевые слова:

жидкостная биопсия

тканевая биопсия

глиомы ствола

диффузная срединная глиома

мутация H3K27m

глиальная опухоль ствола

чувствительность жидкостной биопсии

Авторы:

Гаврюшин А.В.

ФГАУ «Национальный медицинский исследовательский центр нейрохирургии им. акад. Н.Н. Бурденко» Минздрава России;
«Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России

ORCID: 0000-0002-8732-3114

Веселков А.А.

ФГАУ «Национальный медицинский исследовательский центр нейрохирургии им. акад. Н.Н. Бурденко» Минздрава России

ORCID: 0000-0003-2500-3403

Хухлаева Е.А.

ORCID: 0000-0003-2424-5582

Коновалов А.Н.

SPIN РИНЦ: 1462-1783
Scopus AuthorID: 57220527356
ORCID: 0000-0002-5048-0298

Друй А.Е.

«Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России

ORCID: 0000-0003-1308-8622

Дата поступления:

29.03.2024

Дата принятия в печать:

20.09.2024

Список литературы:

Mandel P, Metais P. Nuclear Acids in Human Blood Plasma. Comptes rendus des séances de la Société de biologie et de ses filiales. 1948;142(3-4):1916-1917.
Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914-1922. https://doi.org/10.1212/WNL.0b013e3181c47cc2
Martino G, Grimaldi LME, Moiola L. Discontinuos distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. Journal of Neuroimmunology. 1990;30(2):129-134. https://doi.org/10.1016/0165-5728(90)90096-6
Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chimica Acta. 2001;310(2):173-186. https://doi.org/10.1016/S0009-8981(01)00573-3
Jones J, Nguyen H, Drummond K, Morokoff A. Circulating Biomarkers for Glioma: A Review. Neurosurgery. 2021;88(3):E221-E230. https://doi.org/10.1093/neuros/nyaa540
Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes and Development. 2017;31(18):1827-1840. https://doi.org/10.1101/gad.305805.117
Malapelle U, Pisapia P, Rocco D, Smeraglio R, di Spirito M, Bellevicine C, Troncone G. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Translational Lung Cancer Research. 2016;5(5):505-510. https://doi.org/10.21037/tlcr.2016.10.08
Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, Santos ES, Powery HW. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 2023;24(2):120-129. https://doi.org/10.1016/j.cllc.2022.11.007
Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X, Wu M. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. Journal of Cancer Research and Therapeutics. 2015;11(3):630-634. https://doi.org/10.4103/0973-1482.146121
Wang J, Cazzato E, Ladewig E. Clonal evolution of glioblastoma under therapy. Nature Genetics. 2016;48(7):768-776. https://doi.org/10.1038/ng.3590
Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K, Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Science Translational Medicine. 2014;6(247):247ra101. https://doi.org/10.1126/scitranslmed.3009095
Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber DA, Toner M. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nature Protocols. 2014;9(3):694-710. https://doi.org/10.1038/nprot.2014.044
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annual Review of Cell and Developmental Biology. 2014;30:255-289. https://doi.org/10.1146/annurev-cellbio-101512-122326
Quezada C, Torres Á, Niechi I. Role of extracellular vesicles in glioma progression. Molecular Aspects of Medicine. 2018;60:38-51. https://doi.org/10.1016/j.mam.2017.12.003
Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. Journal of Extracellular Vesicles. 2013;2(1). https://doi.org/10.3402/jev.v2i0.20389
Al-Nedawi K, Meehan B, Micallef J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biology. 2008;10(5):619-624. https://doi.org/10.1038/ncb1725
Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology. 2008;10(12):1470-1476. https://doi.org/10.1038/ncb1800
Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang G, Tofilon PJ, Camphausen KA. Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration. Translational Oncology. 2013;6(6):638-648. https://doi.org/10.1593/tlo.13640
Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP Jr, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, T Ting D, Breakefield XO, Stott SL. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications. 2018;9(1):175. https://doi.org/10.1038/s41467-017-02261-1
Manda SV, Kataria Y, Tatireddy BR. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. Journal of Neurosurgery. 2018;128(4):1091-1101. https://doi.org/10.3171/2016.11.JNS161187
Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P, Tsigas D. Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Annals of the New York Academy of Sciences. 2006;1075:278-281. https://doi.org/10.1196/annals.1368.037
García Moreira V, de la Cera Martínez T, Gago González E, Prieto García B, Alvarez Menéndez FV. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clinical Chemistry and Laboratory Medicine. 2006;44(12):1410-1415. https://doi.org/10.1515/CCLM.2006.252
Diehl F, Schmidt K, Choti MA. Circulating mutant DNA to assess tumor dynamics. Nature Medicine. 2008;14(9):985-990. https://doi.org/10.1038/nm.1789
Müllauer L. Next generation sequencing: clinical applications in solid tumours. Memo. 2017;10(4):244-247. https://doi.org/10.1007/s12254-017-0361-1
Bettegowda C, Sausen M, Leary RJ. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 2014;6(224):224ra24. https://doi.org/10.1126/scitranslmed.3007094
Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G, Callens C, Bieche I, Saliou A, Madic J, Rouleau E, Bidard FC, Lantz O, Stern MH, Le Tourneau C, Pierga JY. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology. 2015;9(4):783-790. https://doi.org/10.1016/j.molonc.2014.12.003
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. 2019;25(9):1415-1421. https://doi.org/10.1038/s41591-019-0561-9
Yekula A, Muralidharan K, Rosh ZS, Youngkin AE, Kang KM, Balaj L, Carter BS. Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. Advanced Biology. 2020;4(12):e2000029. https://doi.org/10.1002/adbi.202000029
Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S, Krichevsky AM. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 2012;14(6):689-700. https://doi.org/10.1093/neuonc/nos074
Dong L, Li Y, Han C, Wang X, She L, Zhang H. miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. International Journal of Oncology. 2014;45(2):746-756. https://doi.org/10.3892/ijo/2014/2459
Majchrzak-Celińska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska AM, Nowak S, Baer-Dubowska W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. Journal of Applied Genetics. 2013;54(3):335-344. https://doi.org/10.1007/s13353-013-0149-x
Boisselier B, Gállego Pérez-Larraya J, Rossetto M, Labussière M, Ciccarino P, Marie Y, Delattre JY, Sanson M. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012;79(16):1693-1698. https://doi.org/10.1212/WNL.0b013e31826e9b0a
Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology. 2010;12(2):173-180. https://doi.org/10.1093/neuonc/nop041
Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, Jones HE, Jefferies S, Short SC, Cheng HY, McAleenan A, Higgins JPT, Kurian KM. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro-Oncology. 2022;24(4):528-540. https://doi.org/10.1093/neuonc/noab247
Durślewicz J, Klimaszewska-Wiśniewska A, Antosik P. Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test. Disease Markers. 2020;2020:8880548. https://doi.org/10.1155/2020/8880548
Howden K, Chapman S, Serletis D, Kazina C, Rafay MF, Faury D, Hazrati LN, Jabado N, Vanan MI. Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children. Cureus. 2021;13(11):e19400. https://doi.org/10.7759/cureus.19400
Kang KM, Muralidharan K, Yekula A, Small JL, Rosh ZS, Jones PS, Carter BS, Balaj L. Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. Cancers. 2021;13(6):1227. https://doi.org/10.3390/cancers13061227
Bannykh SI, Mirocha J, Nuno M, Lopategui J, Kandala G. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. Clinical Neuropathology. 2014;33(6):388-398. https://doi.org/10.5414/NP300753
Birkó Z, Nagy B, Klekner Á, Virga J. Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy. International Journal of Molecular Sciences. 2020;21(20):7522. https://doi.org/10.3390/ijms21207522
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, Xu SS. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. British Journal of Cancer. 2015;112(7):1241-1246. https://doi.org/10.1038/bjc.2015.91
Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. Journal of Neurosurgery. 2016;124(1):122-128. https://doi.org/10.3171/2015.1.JNS141577
Wang H, Wang L, Fang C, Li C, Zhang L. Comparison of the diagnostic value of liquid biopsy in leptomeningeal metastases: A systematic review and meta-analysis. Frontiers in Oncology. 2022;12:1079796. https://doi.org/10.3389/fonc.2022.1079796
Greuter L, Frank N, Guzman R, Soleman J. The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review. Cancers. 2022;14(11):2683. https://doi.org/10.3390/cancers14112683
Van Paemel R, Vlug R, De Preter K, Van Roy N, Speleman F, Willems L, Lammens T, Laureys G, Schleiermacher G, Tytgat GAM, Astrahantseff K, Deubzer H, De Wilde B. The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics. 2020;179(2):191-202. https://doi.org/10.1007/s00431-019-03545-y
Kickingereder P, Willeit P, Simon T, Ruge MI. Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases. Neurosurgery. 2013;72(6):873-881; discussion 882; quiz 882. https://doi.org/10.1227/NEU.0b013e31828bf445
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine. 2012;366(10):883-892. https://doi.org/10.1056/NEJMoa1113205
Bauman MMJ, Bouchal SM, Monie DD, Aibaidula A, Singh R, Parney IF. Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma. Neurosurgical Focus. 2022;53(6):E14. https://doi.org/10.3171/2022.9.FOCUS22430
Zuccato JA, Patil V, Mansouri S, Voisin M, Chakravarthy A, Shen SY, Nassiri F, Mikolajewicz N, Trifoi M, Skakodub A, Zacharia B, Glantz M, De Carvalho DD, Mansouri A, Zadeh G. Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. Neuro-Oncology. 2023;25(8):1452-1460. https://doi.org/10.1093/neuonc/noac264
Iriyama C, Murate K, Iba S, Okamoto A, Goto N, Yamamoto H, Kato T, Mihara K, Miyama T, Hattori K, Kajiya R, Okamoto M, Mizutani Y, Yamada S, Tsukamoto T, Hirose Y, Mutoh T, Watanabe H, Tomita A. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases. Cancer Medicine. 2023;12(16):16972-16984. https://doi.org/10.1002/cam4.6329
Takahashi H, Natsumeda M, On J, Watanabe J, Tada M, Shimizu H, Tsukamoto Y, Okada M, Oishi M, Takizawa J, Hayashi Y, Masaki Y, Kakita A, Fujii Y. Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients. Leukemia & Lymphoma. 2023;64(6):1219-1222. https://doi.org/10.1080/10428194.2023.2199895
Pasqualetti F, Rizzo M, Franceschi S, Lessi F, Paiar F, Buffa FM. New perspectives in liquid biopsy for glioma patients. Current Opinion in Oncology. 2022;34(6):705-712. https://doi.org/10.1097/CCO/0000000000000902
Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology. 2022;24(6):855-871. https://doi.org/10.1093/neuonc/noac004
Wu Y, Wang X, Zhang M, Wu D. Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas. Molecules. 2023;28(15):5660. https://doi.org/10.3390/molecules28155660
Gojo J, Pavelka Z, Zapletalova D, Schmook MT, Mayr L, Madlener S, Kyr M, Vejmelkova K, Smrcka M, Czech T, Dorfer C, Skotakova J, Azizi AA, Chocholous M, Reisinger D, Lastovicka D, Valik D, Haberler C, Peyrl A, Noskova H, Pál K, Jezova M, Veselska R, Kozakova S, Slaby O, Slavc I, Sterba J. Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. Frontiers in Oncology. 2020;9:1436. https://doi.org/10.3389/fonc.2019.01436
Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Nand Yadav V, Ravindran R, Bruzek AK, Wadden J, John V, May Babila C, Cummings JR, Rahman Kawakibi A, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venneti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner SL, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro-Oncology. 2022;24(8):1366-1374. https://doi.org/10.1093/neuonc/noac030
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discovery. 2014;4(6):650-661. https://doi.org/10.1158/2159-8290.CD-13-1014
Bounajem MT, Karsy M, Jensen RL. Liquid biopsies for the diagnosis and surveillance of primary pediatric central nervous system tumors: a review for practicing neurosurgeons. Neurosurgical Focus. 2020;48(1):E8. https://doi.org/10.3171/2019.9.FOCUS19712
Poulet G, Massias J, Taly V. Liquid Biopsy: General Concepts. Acta Cytologica. 2019;63(6):449-455. https://doi.org/10.1159/000499337

Закрыть метаданные